Jamie Kennedy, MD
Advanced Heart Failure and Transplant Cardiology · Falls Church, VANPI 1407078694
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,533 of the $4,498 with a category attached, or 78.6%. 19 manufacturers reported payments, led by Abbott at 26.8% of the total. Reporting peaked in 2024 at $1,936 and has fallen 60.4% since, to $767 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in VA, where the typical reported total is $4,498.
Across 89 payments — averaging $50.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Merck$1K
- Actelion Pharmaceuticals US, Inc.$593
- Abiomed$415
- United Therapeutics Corporation$394
- Bayer$244
- plus $477 from 13 others
Across 19 payments — averaging $18,419 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$310K
- Novartis$22K
- Abbott$17K
- Medtronic$1K
What the payments were for
- Travel & lodging$87619%
- Food & beverage$3,53379%
- Education$892%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 19 | $1,205 |
| Merck | 10 | $1,169 |
| Actelion Pharmaceuticals US, Inc. | 10 | $593 |
| Abiomed | 9 | $415 |
| United Therapeutics Corporation | 15 | $394 |
| Bayer | 11 | $244 |
| Amgen | 1 | $99 |
| Medtronic | 1 | $77 |
| Boehringer Ingelheim | 3 | $51 |
| Sandoz | 1 | $45 |
| Lexicon Pharmaceuticals, Inc. | 1 | $35 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Recor Medical Inc | 1 | $23 |
| Novo Nordisk | 1 | $23 |
| Pfizer | 1 | $22 |
| AbbVie | 1 | $22 |
| Melinta Therapeutics, LLC | 1 | $20 |
| AstraZeneca | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WINREVAIR$862
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$555
- Impella$251
- UPTRAVI$238
- CardioMEMS HF System$160
- OPSUMIT$114
How this compares
$4,498 in reported general payments places this provider in the 50th percentile of 43 advanced heart failure and transplant cardiology providers in Virginia.
See all advanced heart failure and transplant cardiology providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 22 | $841,642 |
| JardianceEmpagliflozin | 69 | $88,664 |
| EntrestoSacubitril/Valsartan | 44 | $62,021 |
| EliquisApixaban | 16 | $25,021 |
| FarxigaDapagliflozin Propanediol | 12 | $16,742 |
| Rosuvastatin Calcium | 16 | $709 |
| Spironolactone | 48 | $581 |
| Valsartan | 11 | $408 |
| Metoprolol Succinate | 18 | $406 |
| Furosemide | 29 | $292 |
| Carvedilol | 16 | $275 |
| Atorvastatin Calcium | 15 | $221 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $22 | $866,66338 claims |
| Boehringer IngelheimJardiance | $51 | $88,66469 claims |
| AstraZenecaFarxiga | $17 | $16,74212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 43 advanced heart failure and transplant cardiology providers in Virginia.
Other advanced heart failure and transplant cardiology in Falls Church
- Palak ShahFalls Church$112K
- Shashank DesaiFalls Church$80K
- Michael FlanaganFalls Church$29K
- Lauren CooperFalls Church$21K
- Allman RollinsFalls Church$9K
- Iyad IssehFalls Church$6K
- Timothy WelchFalls Church$4K
- Lena AliFalls Church$2K
- Vanessa BlumerFalls Church$2K
- Amin YehyaNorfolk$398K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.